Technical and procedural updates only. The bill transitioned from the 'Reported in House' version (v2) to the 'Engrossed in House' version (v3), reflecting its passage in the House of Representatives. There are no substantive changes to the legislative text or policy provisions between the two versions.
FDA Modernization Act 3.0
- Sponsor
- Rep. Carter, Earl L. "Buddy" [R-GA-1]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 21, 2026
Bottom line
The bill ensures FDA regulations reflect existing law by updating terminology to formally recognize nonclinical (non-animal) testing methods for drug development.
What it actually does
This bill mandates the Secretary of Health and Human Services, through the Commissioner of Food and Drugs, to publish an interim final rule within one year. This rule will amend specific sections of Title 21 of the Code of Federal Regulations to replace references to "animal" tests with "nonclinical" tests and incorporate the definition of "nonclinical test" from existing law. This action aims to ensure regulatory consistency with the FDA Modernization Act 2.0, which expanded the acceptance of non-animal testing methods for drug development.
Proponents argue
Supporters argue this bill is crucial for fully implementing the FDA Modernization Act 2.0, which aimed to reduce reliance on animal testing by allowing alternative nonclinical methods. They contend it streamlines the drug approval process, encourages innovation in testing, and aligns regulatory language with scientific advancements and ethical considerations regarding animal welfare, ultimately accelerating the availability of new therapies.
Opponents contend
Given that this bill primarily serves as a technical update to align regulations with existing statutory changes, direct opposition is unlikely. Any potential concerns might revolve around the rigor of new nonclinical methods or the process of regulatory change, rather than the core policy of accepting non-animal tests.
The bill is very short and clear, making it highly accessible for quick evaluation by an informed reader.
Section 2(a)
Mandate for Interim Final Rule on Nonclinical Testing Methods
This provision requires the Secretary of Health and Human Services, acting through the FDA Commissioner, to publish an interim final rule within one year of the bill's enactment. This rule must update specific sections of Title 21 of the Code of Federal Regulations by replacing all references to "animal" tests, data, studies, models, and research with "nonclinical" equivalents. It also mandates the inclusion of the statutory definition of "nonclinical test" into several key regulatory sections, ensuring consistency with the FDA Modernization Act 2.0.
Supporters argue
Supporters argue this provision is essential for the full and effective implementation of the FDA Modernization Act 2.0, which already authorized nonclinical testing. They contend it removes regulatory hurdles, fosters innovation in drug development by validating advanced testing methodologies, and aligns FDA practices with modern scientific understanding and ethical standards regarding animal use.
Critics contend
No specific opposition is typically raised against this provision, as it primarily serves as a technical update to align regulations with existing law. Any potential concerns would likely revolve around the rigor of new nonclinical methods, but the bill itself does not introduce new methods, only updates terminology.
Tradeoffs
The primary tension, if any, lies between the speed of regulatory alignment and the thoroughness of public comment periods. The bill addresses this by making the interim final rule immediately effective, balancing rapid implementation with the need for eventual public input.
This subsection states that the interim final rule issued by the Secretary of Health and Human Services shall become immediately effective without requiring the Secretary to demonstrate "good cause" for bypassing the standard public notice and comment period under 5 U.S.C. 553(b)(B).
Section 2(a)(3)
Why it matters:This is a standard legislative technique to expedite regulatory changes, often used for technical or time-sensitive updates. It ensures rapid implementation of a policy already established by prior law, rather than being an evasive maneuver.
Case for: Proponents argue that immediate effectiveness is necessary to quickly align FDA regulations with the existing statutory changes made by the Consolidated Appropriations Act, 2023, thereby removing any ambiguity or delay in implementing nonclinical testing methods. This ensures the benefits of the original act are realized without undue waiting periods.
Case against: Critics might argue that bypassing the "good cause" requirement, even for technical updates, reduces transparency and public participation in the regulatory process. While the changes are largely technical, some stakeholders might prefer the opportunity to comment on the specific wording of the regulatory amendments.
Estimated impact: Ensures rapid implementation of the regulatory changes, potentially accelerating the adoption of nonclinical testing methods in drug development by removing regulatory ambiguity sooner.
This section makes a technical amendment to Section 505 of the Federal Food, Drug, and Cosmetic Act by redesignating the second subsection (z) (which relates to clinical trial diversity action plans and was added by a previous law) as subsection (aa).
Section 2(b)
Why it matters:This is a purely technical legislative fix to resolve a statutory numbering conflict, a common practice in legislative drafting to maintain code consistency and avoid confusion. It is not an attempt to be evasive.
Case for: Supporters argue this is a necessary technical correction to ensure clarity and proper referencing within the Federal Food, Drug, and Cosmetic Act, preventing future confusion regarding statutory citations and maintaining legislative order.
Case against: There is no substantive case against a purely technical amendment that corrects a numbering error, as it has no policy implications beyond improving statutory clarity.
Estimated impact: No direct policy or fiscal impact; solely improves statutory clarity and consistency for legal professionals and regulators.